Graham K. Cooper - Jul 6, 2021 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
Director
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Stock symbol
BEAM
Transactions as of
Jul 6, 2021
Transactions value $
-$270,825
Form type
4
Date filed
7/8/2021, 06:00 PM
Previous filing
Jun 30, 2021
Next filing
Jan 31, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Options Exercise $44.4K +2.61K $17.00 2.61K Jul 6, 2021 Direct F1
transaction BEAM Common Stock Sale -$70.8K -614 -23.49% $115.38 2K Jul 6, 2021 Direct F2, F3
transaction BEAM Common Stock Sale -$23.3K -200 -10% $116.41 1.8K Jul 6, 2021 Direct F2, F4
transaction BEAM Common Stock Sale -$23.7K -200 -11.11% $118.35 1.6K Jul 6, 2021 Direct F2, F5
transaction BEAM Common Stock Sale -$12K -100 -6.25% $119.68 1.5K Jul 6, 2021 Direct F2, F6
transaction BEAM Common Stock Sale -$24.1K -200 -13.33% $120.39 1.3K Jul 6, 2021 Direct F2, F7
transaction BEAM Common Stock Sale -$48.6K -400 -30.77% $121.59 900 Jul 6, 2021 Direct F2, F8
transaction BEAM Common Stock Sale -$12.3K -100 -11.11% $122.85 800 Jul 6, 2021 Direct
transaction BEAM Common Stock Sale -$24.8K -200 -25% $123.76 600 Jul 6, 2021 Direct F2, F9
transaction BEAM Common Stock Sale -$37.3K -300 -50% $124.31 300 Jul 6, 2021 Direct F2, F10
transaction BEAM Common Stock Sale -$12.7K -100 -33.33% $126.51 200 Jul 6, 2021 Direct
transaction BEAM Common Stock Sale -$12.9K -100 -50% $128.67 100 Jul 6, 2021 Direct
transaction BEAM Common Stock Sale -$12.9K -100 -100% $129.38 0 Jul 6, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -2.61K -13.63% $0.00 16.6K Jul 6, 2021 Common Stock 2.61K $17.00 Direct F1, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.04 to $115.88, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.13 to $116.69, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.00 to $118.71, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.67 to $119.68, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.37 to $120.40, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.19 to $121.96, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.64 to $123.88, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.28 to $124.33, inclusive.
F11 The option vests as to one third on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 4.17% each month thereafter until the option is fully vested.